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Abstract 
Parkinson's disease is the most common neurodegenerative disorder after Alzheimer's 
disease. The aim of this study was to investigate the pharmacokinetic parameters of the 
mGluR4 receptor blocker Rapitalam on rabbits. There was developed the method of the 
quantitative determination of Rapitalam in the blood plasma of rabbits using high 
performance liquid chromatography with tandem mass spectrometric detection. The study 
was performed on 12 rabbits (males, weighing between 3,300 to 3,500 g).  In intragastric 
dosing of the substance was administered using a gastric tube in the form of suspension in 
water 0.9 mg/ml, 9 mg/ml, and 90 mg/ml at a dose of 0.3 mg/kg, 3 mg/kg and 30 mg/kg. 
After the administration of the substance blood was sampled through a catheter in a volume 
of 0.5 ml in polypropylene tubes containing 20 µl of 5% EDTA before and 10, 15, 30, 60, 
120, 240, 480, 1440 minutes after administration. The mean absorption time (MAT) of 
Rapitalam was 268.1 minutes or 4.5 hours. The half-life is longtime and it was 176.4 minutes 
(2.9 hours) for intravenous and 362.2 minutes (6.0 hours) for intragastric administration. The 
absolute bioavailability of the intragastric dosing was 26.8%. The main pharmacokinetic 
parameters of the substance was established on rabbits that allow you to optimize the future 
use of it's as a potential drug for the treatment of Parkinson's disease. 
Key words:  Rapitalam, Parkinson's disease, the blood plasma of rabbits, high performance liquid 
chromatography, pharmacokinetic, metabotropic glutamate receptors. 
 
Introduction 
Parkinson's disease belongs to a group of 
neurodegenerative diseases of the brain. The main 
symptoms of Parkinson's are the loss of coordination, 
constraint and slowness when walking, tremor 
(shaking) of hands, feet, chin. Most often Parkinson's 
disease affects the elderly [1]. The pathogenesis of 
the disease is the insufficient synthesis of dopamine 
in the substantia nigra and striatum. Dopamine 
replacement therapy is currently the primary 
approach in the treatment of Parkinson's disease. 
However, levodopa does not slow down the 
continued degeneration of dopaminergic neurons, the 
functional activity of which causes the conversion of 
levodopa into dopamine by action of DOPA 
decarboxylase [6]. Also drugs of levodopa group 
have a large number of side effects, and over time, 
the dosage must be increased, otherwise they lose 
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effectiveness. Therefore, the attending physician of a 
patient suffering from Parkinson's disease has two 
main tasks: to suspend the death of ganglion 
containing dopamine, and reduce the symptom load 
of disease [1]. Progress in the understanding of the 
anatomy and function of basal ganglia has provided 
an opportunity for the development of new drugs for 
the treatment and slowing the progression of 
Parkinson's disease [3]. Although they are trying to 
cure Parkinson's disease, the experts can only 
partially eliminate the symptoms but not the cause 
itself. Today, all the efforts of scientists aimed at 
finding drugs that will not only soften the symptoms 
of the disease, but also stopped the degenerative 
processes responsible for its progression. So 
glutamate receptors have been proposed as promising 
therapeutic targets, since the effects on them allow 
you to change both normal and pathological 
neurotransmission characteristic of the Parkinsonian 
brain. 
The above data indicate the feasibility of 
preclinical study of Rapitalam, mGluR4 receptor 
modulator, to create on its basis drugs that have anti-
Parkinsonian effect [6]. 
The aim of this study was to investigate the 
pharmacokinetic parameters of the mGluR4 receptor 
blocker Rapitalam on rabbits. 
Materials and methods  
There was studied a Rapitalam substance, 
white powder. Rabbits are common animals used 
in studies of pharmacokinetics in accordance with 
the "Manual on experimental (preclinical) study of 
new pharmacological substances" [6]. Moreover, 
these animals are economically beneficial, because 
in the preliminary catheterization of the animals, to 
take samples of blood from each animal at all time 
points. The study was performed on 12 rabbits 
(males, weighing between 3,300 to 3,500 g). 
During the period of adaptation of animals, which 
is lasted 7 days, there was carried out daily 
inspection of their external condition. For the study 
there were selected rabbits with no signs of 
abnormalities in appearance. All animals were kept 
in separate rooms. Rabbits were kept by two in 
steel lattice coops. After a period of adaptation the 
animals were catheterized in the right ear vein and 
kept individually. The basic rules of keep and care 
consistent with the standards given in the manual • 
Guide for the care and use of laboratory animals. 
The National Academy press. –Washington, D.C. 
2011 [9] and regulations approved by all-Union 
State Standard 31886-2012 "Principles of good 
laboratory practice". 12 hours before the start of 
the experiment, catheterized animals were deprived 
of feed with free access to water. The test 
substance was administered on the third day after 
catheterization. Intravenous dosing the test 
substance was administered bolus of 6 rabbits in 
the ear vein in the form of a solution 9 mg/ml in 
propylene glycol at a dose of 3 mg/kg. In 
intragastric dosing of the substance was 
administered using a gastric tube in the form of 
suspension in water 0.9 mg/ml, 9 mg/ml, and 90 
mg/ml at a dose of 0.3 mg/kg, 3 mg/kg and 30 
mg/kg. After the administration of the substance 
blood was sampled through a catheter in a volume 
of 0.5 ml in polypropylene tubes containing 20 µl 
of 5% EDTA before and 10, 15, 30, 60, 120, 240, 
480, 1440 minutes after administration. Blood 
plasma was separated by centrifugation at 5600 g 
for 10 min and stored until analysis at -70 C. 
Sample preparation blood plasma samples was 
performed by protein precipitation with methanol. To 
do this, into a test tube type "Eppendorf" with a 
capacity of 1.5 ml there were added 0.2 µl of plasma 
and 50 µl of internal standard and mixed, after there 
was added 500 µl of МеOH and shaken on a shaker 
for 15 minutes. Then there was performed the 
extraction of the analyte into ultrasonic bath for 15 
minutes. Then the samples were centrifuged at 13000 
rpm and 4 ºC temperature for 30 minutes. The 
supernatant is carefully decanted into vials for 
chromatography and analyzed. 
In quality control solutions and to construct the 
calibration curve as placebo there was used zero 
blood plasma of rabbits. Zero samples of rabbits’ 
blood plasma were prepared in addition to calibration 
standards to confirm the selectivity of the method. 
The quality control solutions were analyzed during 
the researches and they found the error between an 
administered and found quantity of the analyte, 
compared with margins that served as a validation of 
a significance of the obtained results. 
Rapitalam concentration in the blood plasma of 
rabbits was determined using the previously 
developed method of high performance liquid 
chromatography with tandem mass spectrometric 
detection which has high sensitivity and selectivity, 
that allows to determine low concentrations of drug 
(at the level of ng/ml) in various biological matrices 
[13]. Brief characteristic of the method is given in 
table 1. 
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Table 1.  
The conditions of analysis. 
 
Apparatus 
Lliquid chromatograph Thermo Scientific Dionex UltiMate 3000 RS 
Detector Thermo Scientific Velos Pro c HESI. 
Chromatographic conditions 
Guard column Zorbax Eclipce XDB C18 12.5×3.0 mm with a particle size of 5.0 µm 
Column 
Acclaim™ 120 C18 
150×2.1 mm with a particle size of 5.0 µm 
Separate mode Isocratic 
Mobile phase 5 mM Ammonium acetate +0.1% Formic acid: МеСN (60:40) 
Flow rate 0.3 mL/min 
Temperature of samples 5 º C 
Temperature of column 40 º C 
Volume of injection 1 µL  
Retention time of Rapitalam  about 7 min 
Retention time of  IS about 4 min 
Ionization type ESI «+» 
Mass transformation 
Rapitalam:  383,84→367,0; 
IS: 244,7→130,94. 
Temperature of source 300 ºC 
Voltage across source 3000 V 
The remaining parameters are in accordance with an automatic optimization tool. 
 
Main pharmacokinetic parameters were 
calculated in accordance with the methodological 
recommendations for conducting preclinical studies 
of drugs under the editorship of A. N. Mironov [2]. 
Due to Microsoft Office Excel 2010 on the basis of 
the experimentally obtained data there were 
calculated the pharmacokinetic parameters. Outliers 
in each time point were identified using a statistical 
test of Grubbs [4]. This method showed good and 
accurate results [10, 11, 12]. Arithmetic mean values 
and the coefficient of variation (CV) were calculated 
in 6 animals. 
The peak areas of the analyte and internal 
standard 2 were calculated by specialized software 
Xcalibur 2, then the data were transferred to a 
Microsoft Office Excel 2010, where we calculated 
the equation of the calibration curve, statistically 
evaluated deviation, graphically displayed the results 
[13]. Rapitalam concentration in the studied samples 
was calculated in Microsoft Office Excel 2010 from 
the calibration curve. Outliers in each time point were 
identified using a statistical test of Grubbs [4]. If any 
sample value of Z was greater than the critical value 
for a given number of dimensions N, this sample was 
excluded from further calculation of pharmacokinetic 
parameters. So, for N=6 the critical value of Z is 
equal to 1.89, so samples with Z> 1.89 were 
considered outliers. 
Research results 
Into BelSU Clinical and Preclinical Studies 
Centre there was studied the pharmacokinetic of 
Rapitalam in the blood plasma of rabbits after a 
single intravenous administration in dose of 3 mg/kg 
and intragastric administration in the dose of 30 
mg/kg. After analyzing the obtained results, it was 
identified that after intragastric administration the 
maximum concentration of Rapitalam in the blood 
plasma of rabbits is achieved after an average of 480 
minutes (4.0 hours) (Fig. 1). The half-life is longtime 
(362.2 minutes or 6.04 hours). The mean absorption 
time (MAT) of Rapitalam was 268.1 min (4.47 
hours). The absolute bioavailability fa (%) of 
Rapitalam after intragastric administration to rabbits 
was 26.8 %. 
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Figure 1. The averaged pharmacokinetic curves of  Rapitalam in the blood plasma of rabbits after single administration. 
 
The linearity of the pharmacokinetic of 
Rapitalam was studied after a single intragastric 
administration of the drug to rabbits in three 
increasing dosages of 0.3 mg/kg, 3.0 mg/kg and 30 
mg/kg. Based on these data, there was the hypothesis 
of linearity of the pharmacokinetic of Rapitalam. To 
test this hypothesis there was assessed statistically 
significant departures from zero the intercept AUC(0-
1440). The calculation is presented in figure 2. The 
results showed that the free member is insignificant 
different from zero and the hypothesis should be 
considered correct. 
 
 
 
Figure 2. Evaluation of the linear dependence of the AUC(0-1440)ev on dose. 
 
To further evaluate the linearity there were 
constructed concentration influence curves, 
normalized for dose, from time. The results are 
presented in figure 3. 
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Figure 3. The averaged pharmacokineticconcentration curves of  Rapitalam in blood plasma of rabbits (normalized for dose) 
after a single injection. 
 
From figure 3 it can be seen that the 
concentrations, normalized by dose, for the different 
dosages have the same nature and similar value. It is 
observed excess of maximum concentration for the dose 
of 0.3 mg/kg over others. This deviation should be a 
consequence of the higher solubility of a low dose in the 
fluid of the gastrointestinal tract, at low concentration 
the effect of solubilization and uniform distribution of 
Rapitalam throughout the volume. At high 
concentrations, due to the hydrophobic properties of the 
test substance, there is observed the effect of 
agglomeration between the particles, which causes 
differences in normalized concentrations. It should be 
noted that the dependence of the AUC(0-1440) ev on dose is 
linear, and it gives grounds to confirm the linearity of 
the studied range of Rapitalam in the range from 0 to 30 
mg/kg for rabbits. 
 
Conclusions 
1. Performed research of the main pharmacokinetic 
parameters of Rapitalam allowed to develop a method of 
quantitative determination of this substance in the blood 
plasma of rabbits. 
2. The results obtained in the study of 
pharmacokinetic of Rapitalam showed that the decrease in 
its concentration in blood plasma of treated animals is 
quick in a biexponential manner. The mean absorption 
time (MAT) of Rapitalam was 268.1 minutes or 4.5 hours. 
The half-life is longtime and it was 176.4 minutes (2.9 
hours) for intravenous and 362.2 minutes (6.0 hours) for 
intragastric administration. The absolute bioavailability of 
the intragastric dosing was 26.8%. The maximum 
concentration of  Rapitalam was observed on average after 
4 hours. 
3. The study of the linearity of the pharmacokinetic 
showed that the response/dose in a dosing interval from 0 
to 30 µg/kg in rabbits has a linear dependence. 
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